PTC Therapeutics Inc (PTCT)

17.85
NASDAQ : Health Care
Prev Close 17.85
Day Low/High 0.00 / 0.00
52 Wk Low/High 4.03 / 18.69
Avg Volume 917.50K
Exchange NASDAQ
Shares Outstanding 41.24M
Market Cap 758.48M
EPS -4.20
Div & Yield N.A. (N.A)

Latest News

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Albany Molecular Research, Acorda Therapeutics and PTC Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

PTC Therapeutics Announces FDA Advisory Committee Meeting For Ataluren For The Treatment Of Nonsense Mutation Dystrophinopathy

- September 28th is FDA's Tentative Date for Advisory Committee Meeting -

Short Interest In PTC Therapeutics Expands By 20.8%

The most recent short interest data has been released for the 05/15/2017 settlement date, which shows a 1,263,458 share increase in total short interest for PTC Therapeutics Inc , to 7,350,209, an increase of 20.76% since 04/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

PTCT Crosses Above Average Analyst Target

In recent trading, shares of PTC Therapeutics Inc have crossed above the average analyst 12-month target price of $12.40, changing hands for $12.59/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Commit To Buy PTC Therapeutics At $8, Earn 26% Annualized Using Options

Investors eyeing a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $8.55/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $8 strike, which has a bid at the time of this writing of $1.70.

Biotech Premarket Movers: Seres, PTC, Inovio

Biotech Premarket Movers: Seres, PTC, Inovio

Seres Therapeutics, PTC Therapeutics and Inovio Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

PTC Therapeutics Announces Agreement To Acquire Emflaza™ For The Treatment Of Duchenne Muscular Dystrophy In U.S.

- Emflaza is the first treatment approved in the U.S. for DMD patients 5 years and older, regardless of genetic mutation

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Biotech Premarket Movers: PTC, Teligent, Minerva

Biotech Premarket Movers: PTC, Teligent, Minerva

PTC Therapeutics, Teligent and Minerva Neurosciences were among the biotech stock movers in premarket trading on Monday.

Relative Strength Alert For PTC Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Biotech Premarket Movers: Aurinia, Puma, PTC, Juno

Biotech Premarket Movers: Aurinia, Puma, PTC, Juno

Aurinia Pharmaceuticals, Puma Biotechnology, PTC Therapeutics and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.

PTC Therapeutics Suffers Cystic Fibrosis Setback, Dimming Hopes for Any U.S. Approvals

PTC Therapeutics Suffers Cystic Fibrosis Setback, Dimming Hopes for Any U.S. Approvals

The latest setback occurred in a phase III study of cystic fibrosis patients, where treatment with ataluren over 48 weeks failed to improve lung function compared to a placebo.

Noteworthy Friday Option Activity: PTCT, UVV, SREV

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in PTC Therapeutics Inc , where a total volume of 6,944 contracts has been traded thus far today, a contract volume which is representative of approximately 694,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 101.6% of PTCT's average daily trading volume over the past month, of 683,330 shares.

PTC Therapeutics Announces Third Annual STRIVE Grant Award Program For Duchenne Muscular Dystrophy

-Grant Proposals from Nonprofit Patient Advocacy Organizations Due May 31, 2017-

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

There are 250 Duchenne patients starting the process to receive reimbursement and treatment with Exondys 51, Sarepta says.